Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Thermo Fisher completes $17.4 billion acquisition of PPD, a leading clinical research organization with more than 26,000 colleagues operating in nearly…
Thermo Fisher acquires clinical research services provider PPD for $17.4 billion, expanding its position in the $50 billion clinical research services industry.
Full year 2025 revenue grew 4% to $44.56 billion; PPD remains a Thermo Fisher industry-leading brand (no divestiture), confirming the acquisition thesis…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Thermo Fisher Scientific acquired PPD, a leading clinical research organization, for $47.50 per share in cash (approximately $17.4 billion enterprise value). The acquisition expanded Thermo Fisher's clinical research services capabilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / PPD Inc. (this deal) | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2021 deals · Thermo Fisher Scientific Inc. deals · Multiple (undisclosed) deals